STOCKHOLM Recent study results confirm that two agents from the sodium-glucose cotransporter 2 (SGLT2) inhibitor class can significantly cut the incidence of adverse cardiovascular events in patients with heart failure with reduced ejection fraction (HFpEF), a disease especially common in people with type 2 diabetes, obesity, or both.
And findings from secondary analyses of the studies including one reported last week during the European Association for the Study of Diabetes (EASD) 2022 Annual Meeting show that these SGLT2 inhibitors work as well for cutting incident adverse events (cardiovascular death or worsening heart failure) in patients with HFpEF and diabetes as they do for people with normal blood glucose levels.
But delivering treatment with these proven agents, dapagliflozin (Farxiga) and empagliflozin (Jardiance), first requires diagnosis of HFpEF, a task that clinicians have historically fallen short in accomplishing.
When a year ago, results from the EMPEROR-Preserved trial with empagliflozin and when a few weeks ago results from the DELIVER trial with dapagliflozin established the efficacy of these two SGLT2 inhibitors as the first treatments proven to benefit patients with HFpEF, they also raised the stakes for clinicians to be much more diligent and systematic in evaluating people at high risk for developing HFpEF because of having type 2 diabetes or obesity, two of the most potent risk factors for this form of heart failure.
"Vigilance for HFpEF needs to increase because we can now help these patients," declared Lars H. Lund, MD, PhD, speaking at the meeting. "Type 2 diabetes dramatically increases the incidence of HFpEF," and the mechanisms by which it does this are "especially amenable to treatment with SGLT2 inhibitors," said Lund, a cardiologist and heart failure specialist at the Karolinska Institute, Stockholm.
HFpEF has a history of going undetected in people with type 2 diabetes, an ironic situation given its high incidence as well as the elevated rate of adverse cardiovascular events when heart failure occurs in patients withtype 2 diabetes compared with patients who do not have diabetes.
The key, say experts, is for clinicians to maintain a high index of suspicion for signs and symptoms of heart failure in people with type 2 diabetes and to regularly assess them, starting with just a few simple questions that probe for the presence of dyspnea, exertional fatigue, or both, an approach not widely employed up to now.
Clinicians who care for people with type 2 diabetes must become "alert to thinking about heart failure and alert to asking questions about signs and symptoms" that flag the presence of HFpEF, advised Naveed Sattar, MBChB, PhD, a professor of metabolic medicine at the University of Glasgow, United Kingdom.
Soon, medical groups will issue guidelines for appropriate assessment for the presence of HFpEF in people with type 2 diabetes, Sattar predicted in an interview.
"You can't simply ask patients with type 2 diabetes whether they have shortness of breath or exertional fatigue and stop there," because often their first response will be no.
"Commonly, patients will initially say they have no dyspnea, but when you probe further, you find symptoms," noted Mikhail N. Kosiborod, MD, co-director of Saint Luke's Cardiometabolic Center of Excellence in Kansas City, Missouri.
These people are often sedentary, so they frequently don't experience shortness of breath at baseline, Kosiborod said in an interview. In some cases, they may limit their activity because of their exertional intolerance.
Once a person's suggestive symptoms become known, the next step is to measure the serum level of N-terminal pro-B-type natriuretic peptide (NT-proBNP), a biomarker considered to be a generally reliable signal of existing heart failure when elevated.
Any value above 125 pg/mL is suggestive of prevalent heart failure and should lead to the next diagnostic step of echocardiography, Sattar said.
Elevated NT-proBNP has such good positive predictive value for identifying heart failure that it is tempting to use it broadly in people with type 2 diabetes. A consensus report from the American Diabetes Association that was published earlier this year says that "measurement of a natriuretic peptide [such as NT-proBNP] or high-sensitivity cardiac troponin is recommended on at least a yearly basis to identify the earliest HF [heart failure] stages and implement strategies to prevent transition to symptomatic HF."
But because of the relatively high current price for an NT-proBNP test, the cost-benefit ratio for widespread annual testing of all people with type 2 diabetes would be poor, some experts caution.
"Screening everyone may not be the right answer. Hundreds of millions of people worldwide" have type 2 diabetes. "You first need to target evaluation to people with symptoms," advised Kosiborod.
He also warned that a low NT-proBNP level does not always rule out HFpEF, especially among people with type 2 diabetes who also have overweight or obesity, because NT-proBNP levels can be "artificially low" in people with obesity.
Other potential aids to diagnosis are assessment scores that researchers have developed, such as the H2FPEF score, which relies on variables that include age, obesity, and the presence of atrial fibrillation and hypertension.
However, this score also requires an echocardiography examination, another test that would have a questionable cost-benefit ratio if performed widely for patients with type 2 diabetes without targeting, Kosiborod said.
A prespecified analysis of the DELIVER results that divided the study cohort on the basis of their glycemic status proved the efficacy of the SGLT2 inhibitor dapagliflozin for patients with HFpEF regardless of whether or not they had type 2 diabetes, prediabetes, or were normoglycemic at entry into the study, Silvio E. Inzucchi, MD, reported at the EASD meeting.
Treatment with dapagliflozin cut the incidence of the trial's primary outcome of cardiovascular death or worsening heart failure by a significant 18% relative to placebo among all enrolled patients.
The new analysis reported by Inzucchi showed that treatment was associated with a 23% relative risk reduction among those with normoglycemia, a 13% reduction among those with prediabetes, and a 19% reduction among those with type 2 diabetes, with no signal of a significant difference among the three subgroups.
"There was no statistical interaction between categorical glycemic subgrouping and dapagliflozin's treatment effect," concluded Inzucchi, director of the Yale Medicine Diabetes Center, New Haven, Connecticut.
He also reported that among the 6259 people in the trial with HFpEF, 50% had diabetes, 31% had prediabetes, and a scant 19% had normoglycemia. The finding highlights once again the high prevalence of dysglycemia among people with HFpEF.
Previously, a prespecified secondary analysis of data from the EMPEROR-Preserved trial yielded similar findings for empagliflozin that showed the agent's efficacy for people with HFpEF across the range of glucose levels.
The DELIVER trial was funded by AstraZeneca, the company that markets dapagliflozin (Farxiga). The EMPEROR-Preserved trial was sponsored by Boehringer Ingelheim and Eli Lilly, the companies that jointly market empagliflozin (Jardiance). Lund has been a consultant to AstraZeneca and Boehringer Ingelheim and to numerous other companies, and he is a stockholder in AnaCardio. Sattar has been a consultant to and has received research support from AstraZeneca and Boehringer Ingelheim, and he has been a consultant to Eli Lilly, Afimmune, Amgen, Hammi, Merck Sharpe & Dohme, Novartis, Novo Nordisk, Pfizer, Roche, and Sanofi-Aventis. Kosiborod has been a consultant to and has received research funding from AstraZeneca and Boehringer Ingelheim and has been a consultant to Eli Lilly and numerous other companies. Inzucchi has been a consultant to and has given talks on behalf of AstraZeneca and Boehringer Ingelheim. He has also been a consultant to or has served on trial committees for Abbott, Esperion, Lexicon, Merck, Novo Nordisk, Pfizer, and vTv Therapetics.
European Association for the Study of Diabetes (EASD) 2022 Annual Meeting:Presented September 22, 2022.
Mitchel L. Zoler is a reporter with Medscape and MDedge based in the Philadelphia area. @mitchelzoler
For more diabetes and endocrinology news, follow us on Twitter and Facebook.
You can also follow Medscape on Instagram, YouTube and Linkedin.
Read more from the original source:
Improve Diagnosis of Type of Heart Failure Common in Diabetes - Medscape
- Virginia to offer diabetes-prevention classes - Essentia Health - March 1st, 2024
- Type 2 Diabetes: Red Light Therapy May Help Lower Blood Sugar - Healthline - March 1st, 2024
- Ultra-processed foods linked to over 30 health issues, from diabetes to heart trouble to cancer, research finds - CBS News - March 1st, 2024
- Mayo Clinic Minute: Expanding the living kidney donor pool to those with Type 2 diabetes - Mayo Clinic - March 1st, 2024
- Sugar tax shows sweet results in cutting obesity and diabetes rates - News-Medical.Net - March 1st, 2024
- What's the Connection Between Diabetes and Oral Health? - Medscape - March 1st, 2024
- ATTD 2024: Previewing the Latest on AID Systems, CGMs, and Diabetes Medications - diaTribe Foundation - March 1st, 2024
- What I Wish I Had Known When I Was Diagnosed with Type 2 Diabetes - EatingWell - March 1st, 2024
- Ultraprocessed foods linked to heart disease, diabetes, mental disorders and early death, study finds - CNN - March 1st, 2024
- Type 2 diabetes: Red light therapy could help lower blood sugar levels - Medical News Today - March 1st, 2024
- Unraveling the Link Between Type 2 Diabetes and Lower Back Pain: A New Frontier in Medical Research - Medriva - March 1st, 2024
- Scientists from 18 countries join forces to put end to 'pervasive, global problem' of diabetes stigma and discrimination - Medical Xpress - March 1st, 2024
- Bariatric surgery more effective than medical and lifestyle interventions for diabetes control and remission: Study - Medical Xpress - March 1st, 2024
- Unveiling Growth Prospects in the Type 2 Diabetes Industry: Major Drivers And Lucrative Segments As Per The ... - GlobeNewswire - March 1st, 2024
- Insulin-inhibitory receptor research offers hope for type 2 diabetes therapy - Medical Xpress - March 1st, 2024
- Over 4,800 persons with suspected symptoms of diabetes, hypertension identified during screening - The Hindu - March 1st, 2024
- Free cooking classes to be held in March to prevent Type 2 diabetes in Delco - The Delaware County Daily Times - March 1st, 2024
- Noblesville basketball's Aaron Fine hopes to inspire others with diabetes - IndyStar - March 1st, 2024
- One secret to preventing dementia, diabetes, and heart disease may lie in your oral health habits. Here's the dental ... - Fortune - March 1st, 2024
- Diabetes blood sugar reduction through new technology - The Jerusalem Post - March 1st, 2024
- More Funding to Reduce Costs, Improve Diabetes Care - Government of Nova Scotia - March 1st, 2024
- Many diagnosed with Type 2 diabetes may have a different form of the disease - NBC News - January 14th, 2024
- AI and the safe travel lane of diabetes care - Central Michigan University - January 14th, 2024
- Independent association of history of diabetic foot with all-cause mortality in patients with type 2 diabetes: the Renal ... - Cardiovascular... - January 14th, 2024
- Food an Effective Medicine in Diabetes? - Medscape - January 14th, 2024
- New insight into the pathogenesis of human diabetes - VA News - Veterans Affairs (.gov) - January 14th, 2024
- Controversy surrounding diabetes drug, Ozempic, being used tor weight loss - LiveNOW from FOX - January 14th, 2024
- Why are drugs that help battle obesity and diabetes so hard to get? - The Seattle Times - January 14th, 2024
- Semaglutide linked to lower suicidal ideation risk than other obesity, diabetes drugs - Healio - January 14th, 2024
- 5 "Bad" Carbs You Should Be Eating When You Have Diabetes, According to a Dietitian - EatingWell - January 14th, 2024
- 5 Breakfast Mistakes to Avoid If You Have Diabetes - EatingWell - January 14th, 2024
- Why don't fruit bats get diabetes? New understanding of how they've adapted to a high-sugar diet could lead to ... - The Conversation - January 14th, 2024
- OU professor discovers possible link between breast cancer drugs and Type 2 diabetes - KOCO Oklahoma City - January 14th, 2024
- Regional Union Selects Dario's Cardiometabolic Solution for Diabetes, Hypertension, Weight Management and GLP-1 ... - PR Newswire - January 14th, 2024
- Loneliness Associated With Greater Burden of Care Among Caregivers of Children With Type 1 Diabetes - Drug Topics - January 14th, 2024
- Is Yogurt Good For Diabetes Or Not? A Review By Nutrition Professionals - MSN - January 14th, 2024
- Health Insurance Coverage and Costs for Type 1 Diabetes Screening - Beyond Type 1 - January 14th, 2024
- MCH to open free diabetes clinic thanks to $500,000 received from the City of Odessa - NewsWest9.com - January 14th, 2024
- Smart pens and insulin pump therapy for people with Type 2 diabetes - Omnia Health Insights - January 14th, 2024
- Tandem Diabetes Care's t:slim X2 Insulin Pump is the First Automated Insulin Delivery System to Integrate with ... - Yahoo Finance - January 14th, 2024
- Why fruit bats can eat tons of sugar without getting diabetes - Popular Science - January 14th, 2024
- Effect of Self-Care Activities and Behaviors on Glycemic Control in Patients With Diabetes at a Tertiary Care Hospital in ... - Cureus - January 14th, 2024
- This Is the Absolute Best Way To Stay Hydrated if You Have Diabetes - Northwest Georgia News - January 14th, 2024
- Artificial sweeteners dont aid weight loss, may increase diabetes, heart disease risk, says WHO - ThePrint - May 17th, 2023
- Diabetes: What It Is, Causes, Symptoms, Treatment & Types - April 23rd, 2023
- Medically supervised weight loss approach helps patients reduce risks of diabetes, heart disease and stroke - ABC4.com - April 23rd, 2023
- Dear Annie: Im worried about my sisters use of diabetes injections to drop a few pounds - OregonLive - February 6th, 2023
- Diabetes Drug Mounjaro Expected To Be Approved For Weight Loss Soon: What To Know And How It Compares To Similar Drugs - Forbes - February 6th, 2023
- Alcohol: Some People Have Higher Risk Of Heart Attack, Diabetes And Stroke More Than Binge Drinkers Signs Youre At Risk - Revyuh - February 6th, 2023
- Still Drinking Green Tea? Doctor Reveals A Healthier Drink With Proven Benefits For Diabetes, Aging, Oxidative Stress, And Cancer - Revyuh - January 4th, 2023
- How Cinnamon Lowers Blood Sugar and Fights Diabetes - Healthline - December 27th, 2022
- Diabetic Foot Ulcers: Causes and Treatments - Healthline - December 27th, 2022
- Diabetes: Are jaggery and honey healthier alternatives to sugar? Experts help you understand - Times of India - December 2nd, 2022
- Diabetes | Sutter Health - November 24th, 2022
- Effect of diet on type 2 diabetes mellitus: A review - PMC - November 24th, 2022
- Efficacy of Berberine in Patients with Type 2 Diabetes - PMC - November 24th, 2022
- First Drug to Delay Type 1 Diabetes Approved by FDA - Smithsonian Magazine - November 24th, 2022
- Learn how to prevent and manage diabetes - Lincoln Journal Star - October 29th, 2022
- Resilience may improve health among older adults with type 2 diabetes - Medical News Today - October 13th, 2022
- Years of Diabetes Could Speed Onset of Menopause | Health | derbyinformer.com - The Derby Informer - October 13th, 2022
- Insulin Use May Predict the Development of Diabetic Retinopathy - MD Magazine - October 13th, 2022
- The Most Crucial Eating Habit To Prevent Diabetes - Eat This, Not That - October 13th, 2022
- 2 Northeast Ohio teens born with type 1 diabetes deal with social anxieties of their condition at school - WKYC.com - October 13th, 2022
- University Hospitals nationally recognized for efforts to reduce uncontrolled blood pressure; address relationship between diabetes, heart disease,... - October 13th, 2022
- 5 Analysts Have This to Say About Tandem Diabetes Care - Tandem Diabetes Care (NASDAQ:TNDM) - Benzinga - October 13th, 2022
- Living with diabetes: Nutrition, exercise, routines, and more - Medical News Today - October 4th, 2022
- Cleveland Clinic - October 4th, 2022
- Researchers study long-term effectiveness of diabetes drugs - GW Hatchet - October 4th, 2022
- Once-weekly insulin icodec demonstrates superior reduction in HbA1c in combination with a dosing guide app versus once-daily basal insulin in people... - October 4th, 2022
- THE DIABETES LINK LAUNCHES TO HELP YOUNG ADULTS THRIVE WHILE LIVING WITH THE DISEASE - PR Newswire - October 4th, 2022
- Why people with diabetes have more UTIs and how to prevent infections - Medical News Today - October 4th, 2022
- Dealing With Type 1 Diabetes - Nick Jonas Behind New Men's Mental Health Initiative - Men's Health - October 4th, 2022
- Bionic pancreas improves type 1 diabetes management compared to standard insulin delivery methods - National Institutes of Health (.gov) - October 4th, 2022
- NOACs or Warfarin in Atrial Fibrillation With Diabetes - DocWire News - October 4th, 2022
- Why Type 1 Diabetes Is Tougher on Girls Than Boys - Healthline - October 4th, 2022
- Insights on the Next Generation Diabetes Therapy and Drug Delivery Global Market to 2030 - Rising Incidences of Diabetes Globally and Increase in the... - October 4th, 2022
- Diabetes: TXNIP involved in increased secretion of glucagon from pancreatic alpha cells - University of Alabama at Birmingham - October 4th, 2022
- Peanut Butter and Diabetes: Can They Work Together? - Taste of Home - October 4th, 2022
- Prevalence of Microalbuminuria and Cardiovascular Risk Factors in Patients With Diabetes Mellitus Type-II in Al-Khobar, Kingdom of Saudi Arabia -... - October 4th, 2022
- Do Well, Be Well with Diabetes program starts Oct. 6 in Waco - AgriLife Today - September 25th, 2022